41 completed, 4 terminated, 3 recruiting, 2 unknown. 52 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 52 | Completed 41, Terminated 4, Recruiting 3, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tigulixostat (IBI128) vs Febuxostat in Gout Febuxostat, Tigulixostat - Gout | Phase 3 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 600 | 2026-03-17 | 2026-09-01 |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout Allopurinol, Dotinurad - Gout | Phase 3 | Recruiting | Crystalys Therapeutics | 500 | 2025-08-01 | 2026-11-12 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 866 | 2025-03-11 | 2026-09-28 |
| Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis Etoricoxib + Betamethasone fixed dose, Etoricoxib fixed dose - Gout Arthritis, Gout Attack | Phase 3 | Recruiting | Laboratorios Silanes S.A. de C.V. | 72 | 2025-01-27 | 2025-04-03 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 818 | 2024-06-26 | 2026-10-14 |
| Extension Study of ABP-671 in Participants With Gout ABP-671, Allopurinol - Gout | Phase 2 / Phase 3 | Terminated | Atom Therapeutics Co., Ltd | 43 | 2024-04-22 | 2025-07-16 |
| Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia | Phase 2 / Phase 3 | Unknown | Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd | 636 | 2024-04-22 | 2024-09-19 |
| A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis Qingzhu Granules, Qingzhu Granules Placebo - Gouty Arthritis | Phase 3 | Completed | Tasly Pharmaceutical Group Co., Ltd | 472 | 2023-11-07 | 2026-02-27 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration Adenuric - Gout | Phase 3 | Completed | University Hospital, Rouen | 9 | 2023-08-02 | 2026-11-06 |
| Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Tigulixostat, Allopurinol, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 2202 | 2023-03-30 | 2025-07-22 |
| A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg - Gout | Phase 3 | Completed | JW Pharmaceutical | 612 | 2023-03-21 | 2026-05-04 |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Dapansutrile, Placebo Tablet - Acute Gout Flare, Gout Attack | Phase 2 / Phase 3 | Recruiting | Olatec Therapeutics, Inc. | 300 | 2023-01-06 | 2026-03-11 |
| Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Tigulixostat, Placebo - Gout, Hyperuricemia | Phase 3 | Completed | LG Chem | 354 | 2022-10-25 | 2025-10-29 |
| A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout Dotinurad, Febuxostat, Dotinurad Matched Placebo - Gout | Phase 3 | Completed | Eisai Co., Ltd. | 451 | 2021-12-21 | 2025-07-30 |
| A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout SHR4640, Allopurinol - Gout | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 779 | 2021-06-15 | 2025-01-24 |
| Impact of Colchicine in Hospitalized Colombian Patients With COVID-19 Colchicine 0.5 MG, CONTROL GROUP - Corona Virus Infection | Phase 3 | Terminated | Fundación Universitaria de Ciencias de la Salud | 128 | 2021-04-30 | 2022-02-23 |
| A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout SHR4640 dose1, SHR4640 dose2, Placebo oral tablet - Gout | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 594 | 2019-07-16 | 2022-06-13 |
| Efficacy of Intra-articular NSAID Versus Corticosteroid in the Treatment of Shoulder and Knee Conditions: A Randomized, Double-Blind, Prospective Study Shoulder injection, knee injection - Knee Arthritis, Shoulder Arthritis | Phase 3 | Unknown | OSF Healthcare System | 50 | 2018-08-01 | 2018-08-06 |
| Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis Colchicine opocalcium 1mg, Prednisone : Cortancyl 20mg - Chondrocalcinosis | Phase 3 | Completed | Lille Catholic University | 111 | 2018-02-05 | 2026-04-17 |
Showing 20 of 52. Sign in to see all of them.
Gout (46) · Arthritis, Gouty (10) · Hyperuricemia (9) · Arthritis (7) · Rheumatic Diseases (6) · Genetic Diseases, Inborn (4) · Joint Diseases (4) · Metabolic Diseases (4) · Metabolism, Inborn Errors (4) · Musculoskeletal Diseases (4) · Purine-Pyrimidine Metabolism, Inborn Errors (4) · Renal Insufficiency, Chronic (2) · Arthralgia (1) · Chondrocalcinosis (1) · Coronavirus Infections (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (50) · Nutritional and Metabolic Diseases (50) · Joint Diseases (48) · Musculoskeletal Diseases (48) · Genetic Diseases, Inborn (46) · Metabolic Diseases (46) · Metabolism, Inborn Errors (46) · Purine-Pyrimidine Metabolism, Inborn Errors (46) · Arthritis (45) · Rheumatic Diseases (44) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6)
Allopurinol (15) · Febuxostat (13) · canakinumab (6) · lesinurad (6) · Triamcinolone Acetonide (5) · rilonacept (5) · Colchicine (3) · Pegloticase (3) · Indomethacin (2) · dotinurad (2) · Betamethasone (1) · Celecoxib (1) · Control Groups (1) · Etoricoxib (1) · Interleukin 1 Receptor Antagonist Protein (1)
Novartis Pharmaceuticals (7) · Ardea Biosciences, Inc. (6) · Takeda (6) · Regeneron Pharmaceuticals (5) · Savient Pharmaceuticals (3) · Arthrosi Therapeutics (2) · Atom Therapeutics Co., Ltd (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · LG Chem (2) · Astellas Pharma Taiwan, Inc. (1) · Crystalys Therapeutics (1) · Eisai Co., Ltd. (1) · Fundación Universitaria de Ciencias de la Salud (1) · Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1) · Innovent Biologics Technology Limited (Shanghai R&D Center) (1)
United States (29) · Canada (13) · Australia (11) · Germany (11) · China (8) · Taiwan (8) · New Zealand (7) · Poland (7) · Belgium (6) · South Africa (6) · Spain (6) · Lithuania (5) · Colombia (4) · France (4) · Georgia (4)
Chris Storgard, MD (4) · Robert Evans, PharmD (3) · Hyungjin Cho, MD (2) · Nihar Bhakta, MD (2) · Robert Keenan, MD (2) · Bin Liu, M.D. (1) · Chunde Bao (1) · Eric Houvenagel, Pr (1) · Gowrie Balasubramaniam, MB ChB (1) · Haiwang Ji, M.D. (1) · Hong Liu, M.D. (1)
PMID 21353107, PMID 22052584, PMID 35835008, PMID 18600509, PMID 24122883, PMID 24286509, PMID 24588936, PMID 31203212, PMID 39929260, PMID 16339094, PMID 16439323, PMID 18975369, PMID 19286847, PMID 20131255, PMID 20370912, PMID 21846852, PMID 21849262, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22549879, PMID 23375025, PMID 23485476, PMID 23683134, PMID 24447425, PMID 25028379, PMID 26013187, PMID 27564409, PMID 27821644, PMID 28877949, PMID 29029210, PMID 30073793, PMID 31079535, PMID 31986264, PMID 32020029, PMID 32346093, PMID 38251496, PMID 40897521, PMID 42582081, PMID 42816092
2008 (1), 2009 (1), 2015 (1)